- Assisted a global life sciences company in reclassifying a domestic manufacturing site back into acceptable compliance status following a Form-483.
- Advised a domestic generic drug manufacturer with on-site inspection support and related regulatory meetings with FDA.
- Advised a drug manufacturer on issues related to application integrity.
- Advised multiple India-based generic drug manufacturers with on-site inspections and Form-483 and warning letter responses, including onsite support. Advice was focused on a range of issues including cleaning, data integrity, aseptic processing, computer systems, high-performance liquid chromatography, microbial contamination, and other manufacturer and testing-related issues.
- Advised laboratory developed tests (LDT) manufacturers on specific regulatory issues for their products as well as the FDA’s plan to transition away from the LDT enforcement policy.
- Advised a domestic food manufacturing facility with a microbiological contamination issue.
- Assisted with the submission of an Investigational New Drug (IND) application on behalf of the developer of a SARS-CoV-2 vaccine. Alston & Bird’s work included a protocol review, as well as advice regarding the delivery system for the vaccine and assistance addressing FDA questions regarding the application.
- Designed, directed manufacturing procedures, and ensured regulatory compliance of medical devices.
- Developed policies and standards for post-market regulation of laboratory-developed tests (LDTs), the manufacture of medical devices, submission review, inspection, and FDA enforcement.
- Assisted makers and importers of medical devices, pharmaceuticals, food, raw pet food, baby formula, and tobacco products in conducting recalls.
Benjamin K. Wolf
Partner,
- Phone: +1 202 239 3035
- Email: ben.wolf@alston.com
Ben advises clients regulated by the FDA on navigating complex regulatory risk across the product lifecycle, with a focus on medical and tobacco products. A former FDA regulatory counsel and medical device engineer, he helps clients anticipate and respond to FDA scrutiny, align regulatory strategy with business objectives, and manage enforcement, inspection, and compliance challenges.